The most widely used form of hormonal contraception is the combination oral contraceptive (OC). Combination OCs can be monophasic, providing the same dose of estrogen and progestin daily, or multiphasic, offering varying doses of hormones throughout a 21- or 28-day cycle. The objective of OCs is to suppress ovulation by manipulating events throughout the ovulatory cycle to prevent pregnancy. The progestin and estrogen components of OCs suppress the mid-cycle surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The overall effect is to decidualize the endometrial bed and suppress mitotic activity. Initial formulations of OCs in the 1960s attempted to mimic the natural cycle; however, providing high doses of estrogen rather than lower doses of combined estrogen and progestin resulted in greater risk of serious adverse events. Today, OCs provide far lower levels of estrogen and progestin. The availability of formulations with drospirenone, a unique progestin pharmacokinetically similar to progestin and similar in structure to spironolactone, should widen usage of OCs. Although OCs are still associated with increased risk in certain patients and are contraindicated in others, they remain effective but require diligent usage.

Download full-text PDF

Source

Publication Analysis

Top Keywords

estrogen progestin
12
ocs suppress
8
ocs
7
progestin
6
estrogen
5
oral contraceptives
4
contraceptives mechanism
4
mechanism action
4
action dosing
4
dosing safety
4

Similar Publications

Background/objective: 4H syndrome is a rare form of leukodystrophy characterized by hypomyelination, hypodontia, and hypogonadotropic hypogonadism. In 95% of cases, hypomyelination is present, but other clinical features, such as hypodontia and hypogonadotropic hypogonadism, are not always present and may not be necessary for diagnosis. Hypogonadotropic hypogonadism is the most common endocrine complication that can occur in 4H syndrome.

View Article and Find Full Text PDF

Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disease characterized by recurrent painful nodules, abscesses and sinus tract on the apocrine gland-bearing skin. The role of sex hormones in the pathogenesis as well as the use of hormonal treatment in the management of HS is still debated. We performed a retrospective cohort study including 183 patients to assess the influence of combined estrogen-progestin oral contraceptive (COC) in HS onset and disease severity.

View Article and Find Full Text PDF
Article Synopsis
  • A 46-year-old woman on low-dose estrogen-progestin therapy for endometriosis developed a right-sided pneumothorax, which is a collapsed lung.
  • Surgical investigation revealed a pulmonary bulla and a small diaphragm defect, leading to the discovery of endometrial tissue in the lung, thus diagnosing thoracic endometriosis.
  • This case highlights that catamenial pneumothorax can still happen in patients receiving hormonal treatment for endometriosis, indicating the need for ongoing awareness among clinicians.
View Article and Find Full Text PDF

Undifferentiated endometrial carcinoma diagnosed during perimenopausal hormone therapy: a case report and literature review.

Front Oncol

November 2024

The Taizhou Central Hospital (Taizhou University Hospital), School of Medicine, Taizhou University, Taizhou, Zhejiang, China.

Uterine corpus endometrial carcinoma, one of the three most frequent cancers of the female reproductive system, primarily affects women who are perimenopausal or postmenopausal. Moreover, it is an epithelial cancer that develops in the endometrium, which is classified as either estrogen-dependent (type I) or non-estrogen-dependent (type II). Non-estrogen-dependent endometrial cancers include plasma cell carcinoma and undifferentiated/dedifferentiated endometrial carcinoma.

View Article and Find Full Text PDF

Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices.

Hematology Am Soc Hematol Educ Program

December 2024

Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Hormonal contraceptive therapy (estrogens and/or progestogens) includes different formulations associated with varying venous thromboembolism (VTE) risks. The thrombogenicity of combined hormonal contraceptives (CHCs) is due at least in part to multiple changes in clotting factors and the vasculature and is dependent on both estrogen dose and type of progestin. Transdermal patch and vaginal ring users have similar or higher VTE risk as combined oral contraceptive users.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!